Bulletin
Investor Alert

London Markets Open in:

Market Pulse Archives

Oct. 27, 2020, 9:52 a.m. EDT

Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Novavax Inc. /zigman2/quotes/202614340/composite NVAX +10.99% gained 2.9% in trading on Tuesday after the company said it expects to launch a Phase 3 trial for its COVID-19 vaccine candidate in Mexico and the U.S. by the end of next month. It already started a late-stage trial for its vaccine in the U.K. in September. Novavax has published some data for its experimental COVID-19 vaccine from its Phase 1 clinical trial, in September in the New England Journal of Medicine. It said Tuesday it plans to present new reactogenicity data from the Phase 2 trial on Friday, during an advisory committee on immunization practices meeting convened by the Centers for Disease Control and Prevention. Novavax's stock has soared 2,180.1% so far this year, compared with the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.46% , which is up 5.2%.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 139.50
+13.81 +10.99%
Volume: 16.39M
Nov. 30, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$8.00 billion
Rev. per Employee
$113,103
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,621.63
-16.72 -0.46%
Volume: 3.65B
Nov. 30, 2020 5:34p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.